13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001674712
Total reported value
$1.1B
$1.1B
47 檔
61.5%
According to the latest 13F quarterly dataset, Vivo Capital, LLC managed an equity portfolio of $1.1B at the end of Q4 2025, spanning 47 distinct U.S. exchange-listed positions.
In Q4 2025, Vivo Capital, LLC adopted a defensive or profit-taking posture, trimming 9 positions and completely liquidating 7 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 13.96% | -5.85% | EXIT | |
| 2 | CDTX | Cidara Therapeutics Inc | Stock-Other | 13.66% | — | -27.05% | |
| 3 | PRAX | Praxis Precision Medicines I | Stock-Other | 6.27% | -0.79% | +65.36% | |
| 4 | COGT | Cogent Biosciences Inc | Stock-Other | 5.51% | -1.35% | EXIT | |
| 5 | TRVI | Trevi Therapeutics Inc | Stock-Other | 4.12% | +3.63% | — | |
| 6 | ✓ | Avadel Pharmaceuticals PLC ADR | Stock-Other | 3.74% | — | — | |
| 7 | CMPX | Compass Therapeutics Inc | Stock-Other | 3.31% | -2.65% | — | |
| 8 | DYN | Dyne Therapeutics Inc | Stock-Other | 3.31% | +0.81% | — | |
| 9 | ABVX | Abivax Sa-adr | Stock-Other | 3.13% | +2.83% | — | |
| 10 | DBVT | Dbv Technologies Sa-spon Adr | Stock-Other | 3.05% | -1.87% | +133.44% | |
| 11 | SABS | Sab Biotherapeutics Inc | Stock-Other | 2.76% | -1.04% | — | |
| 12 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 2.68% | -0.82% | EXIT | |
| 13 | DRUG | Bright Minds Biosciences Inc | Stock-Other | 2.53% | +0.19% | — | |
| 14 | SVA | Sinovac Biotech Ltd. | Stock-Other | 2.47% | +0.32% | — | |
| 15 | GERN | Geron CORP | Stock-Other | 2.32% | -0.06% | — | |
| 16 | ERAS | Erasca Inc | Stock-Other | 2.23% | -9.44% | — | |
| 17 | ZBIO | Zenas Biopharma Inc | Stock-Other | 2.00% | — | -27.87% | |
| 18 | VRDN | Viridian Therapeutics Inc | Stock-Other | 1.98% | -0.27% | EXIT | |
| 19 | ACRS | Aclaris Therapeutics Inc | Stock-Other | 1.73% | +1.15% | — | |
| 20 | CAMP | Camp4 Therapeutics CORP | Stock-Other | 1.68% | +0.13% | +8.29% | |
| 21 | TNGX | Tango Therapeutics Inc | Stock-Other | 1.23% | +0.19% | +177.43% | |
| 22 | ANRO | Alto Neuroscience Inc | Stock-Other | 1.19% | +0.97% | — | |
| 23 | LBRX | Lb Pharmaceuticals Inc | Stock-Other | 1.15% | +0.73% | — | |
| 24 | NERV | Minerva Neurosciences Inc | Stock-Other | 1.12% | +0.03% | — | |
| 25 | ORIC | Oric Pharmaceuticals Inc | Stock-Other | 1.12% | -0.12% | -32.25% | |
| 26 | CRVS | Corvus Pharmaceuticals Inc | Stock-Other | 1.11% | +0.42% | — | |
| 27 | OLMA | Olema Pharmaceuticals Inc | Stock-Other | 1.09% | -0.06% | -55.38% | |
| 28 | PEPG | Pepgen Inc | Stock-Other | 0.98% | +0.04% | — | |
| 29 | DSGN | Design Therapeutics Inc | Stock-Other | 0.98% | +0.70% | — | |
| 30 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 0.94% | +0.68% | — | |
| 31 | MLTX | Moonlake Immunotherapeutics | Stock-Other | 0.85% | +0.94% | — | |
| 32 | CTMX | Cytomx Therapeutics Inc | Stock-Other | 0.79% | — | — | |
| 33 | UNCY | Unicycive Therapeutics Inc | Stock-Other | 0.67% | -0.74% | — | |
| 34 | EPRX | Eupraxia Pharmaceuticals Inc | Stock-Other | 0.66% | — | — | |
| 35 | ABEO | Abeona Therapeutics Inc | Stock-Other | 0.63% | — | — | |
| 36 | VSTM | Verastem Inc | Stock-Other | 0.55% | — | -58.17% | |
| 37 | SLN | Silence Therapeutics Plc-adr | Stock-Other | 0.43% | — | — | |
| 38 | MNPR | Monopar Therapeutics Inc | Stock-Other | 0.38% | +0.36% | — | |
| 39 | SRZN | Surrozen Inc | Stock-Other | 0.38% | -0.01% | — | |
| 40 | PALI | Palisade Bio Inc | Stock-Other | 0.35% | — | — | |
| 41 | SERA | Sera Prognostics Inc-a | Stock-Other | 0.31% | -0.01% | — | |
| 42 | TIL | Instil Bio Inc | Stock-Other | 0.21% | +0.01% | — | |
| 43 | KTTA | Pasithea Therapeutics CORP | Stock-Other | 0.18% | -0.11% | — | |
| 44 | TENX | Tenax Therapeutics Inc | Stock-Other | 0.16% | +3.04% | — | |
| 45 | ✓ | Engene Holdings Inc | Stock-Other | 0.05% | — | — | |
| 46 | BOLT | Bolt Biotherapeutics Inc | Stock-Other | 0.03% | +0.01% | -58.87% | |
| 47 | DTIL | Precision Biosciences Inc | Stock-Other | — | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | 430 | Terns Pharmaceuticals Inc | +9.8% | -22.46% | Trim |
| 2 | PRAX | Praxis Precision Medicines I | +5.4% | +65.36% | Add |
| 3 | CDTX | Cidara Therapeutics Inc | +3.6% | -27.05% | Trim |
| 4 | COGT | Cogent Biosciences Inc | +2.3% | -13.99% | Trim |
| 5 | DBVT | Dbv Technologies Sa-spon Adr | +2.2% | +133.44% | Add |
| 6 | SABS | Sab Biotherapeutics Inc | +0.9% | — | Unchanged |
| 7 | CAMP | Camp4 Therapeutics CORP | +0.7% | +8.29% | Add |
| 8 | TNGX | Tango Therapeutics Inc | +0.7% | +177.43% | Add |
| 9 | ABVX | Abivax Sa-adr | +0.7% | — | Unchanged |
| 10 | DYN | Dyne Therapeutics Inc | +0.7% | — | Unchanged |
| 11 | CMPX | Compass Therapeutics Inc | +0.6% | — | Unchanged |
| 12 | ERAS | Erasca Inc | +0.6% | — | Unchanged |
| 13 | ✓ | Avadel Pharmaceuticals PLC ADR | +0.4% | — | Unchanged |
| 14 | TRVI | Trevi Therapeutics Inc | +0.4% | — | Unchanged |
| 15 | ACRS | Aclaris Therapeutics Inc | +0.4% | — | Unchanged |
| 16 | VRDN | Viridian Therapeutics Inc | +0.3% | — | Unchanged |
| 17 | LBRX | Lb Pharmaceuticals Inc | +0.1% | — | Unchanged |
| 18 | PEPG | Pepgen Inc | +0.1% | — | Unchanged |
| 19 | SRZN | Surrozen Inc | +0.1% | — | Unchanged |
| 20 | DRUG | Bright Minds Biosciences Inc | +0.1% | — | Unchanged |
| 21 | CTMX | Cytomx Therapeutics Inc | +0.1% | — | Unchanged |
| 22 | UNCY | Unicycive Therapeutics Inc | 0% | — | Unchanged |
| 23 | TENX | Tenax Therapeutics Inc | 0% | — | Unchanged |
| 24 | EPRX | Eupraxia Pharmaceuticals Inc | 0% | — | Unchanged |
| 25 | DTIL | Precision Biosciences Inc | — | — | Unchanged |
| 26 | SLN | Silence Therapeutics Plc-adr | 0% | — | Unchanged |
| 27 | BOLT | Bolt Biotherapeutics Inc | -0.1% | -58.87% | Trim |
| 28 | OLMA | Olema Pharmaceuticals Inc | -0.1% | -55.38% | Trim |
| 29 | SERA | Sera Prognostics Inc-a | -0.1% | — | Unchanged |
| 30 | ZBIO | Zenas Biopharma Inc | -0.1% | -27.87% | Trim |
| 31 | ABEO | Abeona Therapeutics Inc | -0.2% | — | Unchanged |
| 32 | DNTH | Dianthus Therapeutics Inc | -0.2% | — | Unchanged |
| 33 | TIL | Instil Bio Inc | -0.2% | — | Unchanged |
| 34 | MNPR | Monopar Therapeutics Inc | -0.2% | — | Unchanged |
| 35 | CRVS | Corvus Pharmaceuticals Inc | -0.2% | — | Unchanged |
| 36 | SVA | Sinovac Biotech Ltd. | -0.6% | — | Unchanged |
| 37 | GERN | Geron CORP | -0.7% | — | Unchanged |
| 38 | VSTM | Verastem Inc | -1.3% | -58.17% | Trim |
| 39 | ORIC | Oric Pharmaceuticals Inc | -1.9% | -32.25% | Trim |
| 40 | SLNOEUR | Soleno Therapeutics Inc | -9.7% | -60.72% | Trim |
| 41 | VRNA | Verona Pharma PLC - Adr | — | EXIT | Sold out |
| 42 | TRML | Tourmaline Bio Inc | — | EXIT | Sold out |
| 43 | AKRO | Akero Therapeutics Inc | — | EXIT | Sold out |
| 44 | RZLT | Rezolute Inc | — | EXIT | Sold out |
| 45 | ANRO | Alto Neuroscience Inc | — | NEW | New buy |
| 46 | NERV | Minerva Neurosciences Inc | — | NEW | New buy |
| 47 | DSGN | Design Therapeutics Inc | — | NEW | New buy |
| 48 | MLTX | Moonlake Immunotherapeutics | — | NEW | New buy |
| 49 | CATBUSD | Astria Therapeutics Inc | — | EXIT | Sold out |
| 50 | DCTH | Delcath Systems Inc | — | EXIT | Sold out |
According to official SEC Form 13F filings, Vivo Capital, LLC reported a total U.S. public equity portfolio value of $1.1B across 47 disclosed positions in Q4 2025.
During Q4 2025, Vivo Capital, LLC's top holdings by market value included 430 (14.0%)、CDTX (13.7%)、PRAX (6.3%). The largest single position, 430, represented 14.0% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including 430, CDTX, PRAX) accounted for 61.5% of total reported equity market value during Q4 2025.
Top New Position Initiated
ANRO
市值: $18.4M
Top Position Liquidated / Trimmed
VRNA
前期市值: $148.7M
In Q4 2025, Vivo Capital, LLC made 27 total portfolio adjustments, initiating 7 new buys, adding to 4 positions, trimming 9 holdings, and fully liquidating 7 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.